Abstract:Purpose: Our previous study demonstrated the benefit of cumulative dose of cisplatin during the whole treatment on locally advanced nasopharyngeal carcinoma (NPC) treated with various chemotherapy strategies. The purpose of this study is to identify the subgroup of locally advanced NPC who benefits from higher dose of cisplatin, and to clarify whether cumulative dose of cisplatin during the whole treatment brings survival benefit to those treated with concurrent chemoradiotherapy (CCRT).Materials and methods: This retrospective study enrolled 527 patients with locally advanced NPC treated with intensity-modulated radiation therapy (IMRT) and chemotherapy in our institution from 2009 to 2010. The median cumulative dose of cisplatin of 300mg/ m2 was chose to be the cutoff value of low and high dose subgroups. Survival curves were estimated using the Kaplan-Meier method. Univariate analysis was conducted using the log-rank test. Multivariate analyses (MVA) were performed using Cox proportional hazards regression model.Results: With a median follow-up of 54.5 (1-76.7) months, high-dose subgroup had a significant higher distant metastasis-free survival (DMFS) (82.0% vs. 76.5%, p= 0.029) and overall survival (OS) (84.1% vs. 74.0%, p= 0.028). Cumulative dose of cisplatin were demonstrated an independent prognostic factors for DMFS (HR= 0.524, 95% CI 0.340-0.806) and OS (HR= 0.577, 95% CI 0.373-0.893) for the entire cohort upon MVA. As for T1-2N2-3, high-dose subgroup had a trend of better DMFS (85.7% vs. 76.3%, p= 0.069) and a significant improvement in OS (87.8% vs. 76.3%, p= 0.041). Similarly, in the subgroup of T3-4N2-3, higher dose of cisplatin was associated with higher OS (80.3% vs. 52.3%, p= 0.032). Cumulative dose of cisplatin was an independent prognostic factor for DMFS (HR= 0.483, 95% CI 0.292-0.798) and OS (HR= 0.429, 95% CI 0.258-0.715) for patients with T1-4N2-3 disease upon MVA. However, the benefit of higher dose of cisplatin was not observed in the subgroup of T3-4N0-1. For patients receiving CCRT (n= 278), those treated with higher dose of cisplatin had a significantly higher DMFS (87.7% vs. 75.4%, p= 0.004). The benefit mainly derived from T3-4N2-3 patients treated with CCRT (5y DMFS: 87.9% vs. 58.2%, p= 0.034). Cumulative dose of cisplatin was associated with a lower risk of distant metastasis (HR= 0.427, 95% CI 0.228-0.801) for patients treated with CCRT upon MVA.Conclusions: Our study identified that patients with N2-3 disease were those benefited from higher cumulative dose. The benefit of higher cumulative dose maintained in those treated with CCRT. The intensity of chemotherapy may be tailored based on various stage subgroups in locally advanced NPC.

Who Benefited Most from Higher Cumulative Dose of Cisplatin among Patients with Locally Advanced Nasopharyngeal Carcinoma Treated by Intensity-Modulated Radiation Therapy? A Retrospective Study of 527 Cases

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy

Efficiency of high cumulative cisplatin dose in high‐ and low‐risk patients with locoregionally advanced nasopharyngeal carcinoma

Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study

Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost

WITHDRAWN: Interim Analysis of a Prospective Randomized Non-Inferiority Trial of Cisplatin and Fluorouracil Induction Chemotherapy with or Without Docetaxel in Nasopharyngeal Carcinoma

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein-Barr virus DNA level after induction chemotherapy

Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy

Omission of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiation Therapy: A Paired Cohort Study

Long-term survival, toxicities, and the role of chrono-chemotherapy with different infusion rates in locally advanced nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy: a retrospective study with a 5-year follow-up

Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma

A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin

Induction Chemotherapy Combined with Intensity-Modulated Radiotherapy for 129 Nasopharyngeal Carcinoma Patients with Synchronous Metastases: A Retrospective Study

Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy

Combined pre-treatment and middle-treatment Epstein–Barr virus DNA load contributes to prognostication and treatment modification in nasopharyngeal carcinoma patients

Role of Chemoradiotherapy in Intermediate Prognosis Nasopharyngeal Carcinoma

Long-term Efficacy and Adverse Effects of Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma

Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up

Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model

Experience with Combination of Cisplatin Plus Gemcitabine Chemotherapy and Intensity-Modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma